2024-01-31 12:20:25 ET
Boston Scientific Corporation (BSX)
Q4 2023 Earnings Conference Call
January 31, 2024, 8:00 AM ET
Company Participants
Lauren Tengler - Vice President, Investor Relations
Michael Mahoney - Chairman and Chief Executive Officer
Daniel Brennan - Executive Vice President and Chief Financial Officer
Kenneth Stein - Senior Vice President, Global Chief Medical Officer
Jon Monson - Global Controller and Chief Accounting Officer
Janarthanan Sathananthan - Chief Medical Officer
Conference Call Participants
Robert Marcus - JPMorgan
Joanne Wuensch - Citi
Larry Biegelsen - Wells Fargo
Vijay Kumar - Evercore ISI
Danielle Antalffy - UBS
Travis Steed - Bank of America
Josh Jennings - TD Cowen
Richard Newitter - Truist Securities
Patrick Wood - Morgan Stanley
Michael Polark - Wolfe Research
Presentation
Operator
Good morning and welcome to the Boston Scientific Fourth Quarter 2023 Earnings Call. All participants will be in listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note this event is being recorded.
I would now like to turn the conference over to Lauren Tengler, Vice President, Investor Relations. Please go ahead.
Lauren Tengler
Thank you, Drew. Welcome, everyone, and thanks for joining us today. With me on today's call are Mike Mahoney, Chairman and Chief Executive Officer; and Dan Brennan, Executive Vice President and Chief Financial Officer.
We issued a press release earlier this morning announcing our Q4 and full year 2023 results, which included reconciliations of the non-GAAP measures used in the release. We have posted a copy of that release, as well as reconciliations of the non-GAAP measures used in today's call to the Investor Relations section of our website under the heading Financials & Filings.
The duration of this morning's call will be approximately one hour. Mike and Dan will provide comments on Q4 and full year performance, as well as the outlook for the business including 2024 guidance, and then we'll take your questions. During today's Q&A session, Mike and Dan will be joined by our Chief Medical Officer, Dr. Ken Stein.
Before we begin, I'd like to remind everyone that on this call, operational revenue growth, excludes the impact of foreign currency fluctuations, and organic revenue growth further excludes acquisitions and divestitures for which there are less than a full period of comparable net sales....
Read the full article on Seeking Alpha
For further details see:
Boston Scientific Corporation (BSX) Q4 2023 Earnings Call Transcript